Articles | August 15, 2022
– Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai’s development programs with anticipated meaningful near-term clinical value inflections – Key achieved R&D milestones include completion of the clinical phase of the Drug-Drug-Interaction (DDI)… Read More
Articles | August 15, 2022
– Non-dilutive financing facility, plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments – Flexible draw availability provides optionality to optimize liquidity and capital structure moving forward NEW YORK and BERLIN, Aug. Read More
Articles | August 1, 2022
atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update NEW YORK and BERLIN, Aug. 01, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its second quarter 2022… Read More
Articles | June 30, 2022
June 30, 2022 Dr. Chad Beyer will join as CEO on July 1, 2022 NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) — Kures Therapeutics, Inc (“Kures”), an atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) company focused on developing treatment options to better manage addictions, depression, and pain, today announced… Read More
News | June 17, 2022
Stephen Bardin to Join atai Life Sciences as CFO Designate June 17, 2022 Stephen Bardin will join as CFO Designate on June 27, 2022 After a transition period, atai’s current CFO Greg Weaver will be moving into a part time strategic advisory role NEW YORK and BERLIN, June 17, 2022… Read More
JOIN THE ATAI #INSIGHTNETWORK